JP2024546431A5 - - Google Patents

Info

Publication number
JP2024546431A5
JP2024546431A5 JP2024527671A JP2024527671A JP2024546431A5 JP 2024546431 A5 JP2024546431 A5 JP 2024546431A5 JP 2024527671 A JP2024527671 A JP 2024527671A JP 2024527671 A JP2024527671 A JP 2024527671A JP 2024546431 A5 JP2024546431 A5 JP 2024546431A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049607 external-priority patent/WO2023086514A1/en
Publication of JP2024546431A publication Critical patent/JP2024546431A/ja
Publication of JP2024546431A5 publication Critical patent/JP2024546431A5/ja
Pending legal-status Critical Current

Links

JP2024527671A 2021-11-11 2022-11-10 Rna送達のためのイオン化可能なカチオン性脂質 Pending JP2024546431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278242P 2021-11-11 2021-11-11
US63/278,242 2021-11-11
PCT/US2022/049607 WO2023086514A1 (en) 2021-11-11 2022-11-10 Ionizable cationic lipids for rna delivery

Publications (2)

Publication Number Publication Date
JP2024546431A JP2024546431A (ja) 2024-12-24
JP2024546431A5 true JP2024546431A5 (cg-RX-API-DMAC10.html) 2025-12-03

Family

ID=86336481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527671A Pending JP2024546431A (ja) 2021-11-11 2022-11-10 Rna送達のためのイオン化可能なカチオン性脂質

Country Status (13)

Country Link
US (1) US20230295081A1 (cg-RX-API-DMAC10.html)
EP (1) EP4430026A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024546431A (cg-RX-API-DMAC10.html)
KR (1) KR20240128677A (cg-RX-API-DMAC10.html)
CN (1) CN118451059A (cg-RX-API-DMAC10.html)
AR (1) AR127659A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022387111A1 (cg-RX-API-DMAC10.html)
CA (1) CA3237904A1 (cg-RX-API-DMAC10.html)
IL (1) IL312732A (cg-RX-API-DMAC10.html)
MX (1) MX2024005714A (cg-RX-API-DMAC10.html)
TW (1) TW202337498A (cg-RX-API-DMAC10.html)
UY (1) UY40016A (cg-RX-API-DMAC10.html)
WO (1) WO2023086514A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
CN116574070B (zh) * 2023-04-07 2025-10-31 华南理工大学 一种多尾型可电离脂质及其制备方法与应用
WO2024233750A1 (en) * 2023-05-10 2024-11-14 Arcturus Therapeutics, Inc. Ionizable cationic lipids for rna delivery
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
KR20240174509A (ko) * 2023-06-07 2024-12-17 포항공과대학교 산학협력단 핵산 치료제에 사용되는 기능성 지질 라이브러리를 합성하기 위한 단일 연속 유동 합성 방법
WO2025076113A1 (en) * 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL328626A (en) 2023-12-15 2026-07-01 Capstan Therapeutics Inc Humanized anti-CD8 antibodies and their uses
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
DK3221293T3 (da) 2014-11-18 2023-04-03 Arcturus Therapeutics Inc Ioniserbar kationisk lipid til RNA-afgivelse
US9834510B2 (en) 2015-12-30 2017-12-05 Arcturus Therapeutics, Inc. Aromatic ionizable cationic lipid
US10526284B2 (en) 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10227302B2 (en) 2017-02-09 2019-03-12 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2019191780A1 (en) 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery
EP3942050A4 (en) 2019-03-19 2023-02-22 Arcturus Therapeutics, Inc. PROCEDURE FOR THE PRODUCTION OF LIPID-COATED RNA NANOPARTICLES
JP7562995B2 (ja) 2020-06-10 2024-10-08 大日本印刷株式会社 重合性液晶組成物、重合体、位相差フィルム及びその製造方法、転写用積層体、光学部材及びその製造方法、並びに表示装置

Similar Documents

Publication Publication Date Title
JP2024518375A5 (cg-RX-API-DMAC10.html)
CN110522918B (zh) 靶向元件及其制备方法和运用
US8192753B2 (en) pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same
JP5420507B2 (ja) 薬理活性のある化合物の細胞内送達のためのカチオン脂質として有用な、l−カルニチンまたはアルカノイルl−カルニチンのエステル
US5830430A (en) Cationic lipids and the use thereof
CN112826808B (zh) 一种环二核苷酸或其类似物的中性/阳离子混合脂材纳米制剂及其应用
JP2017536092A5 (cg-RX-API-DMAC10.html)
JP2001502299A (ja) リポソーム
CN115867318A (zh) 一种脂质纳米颗粒
JP7832717B2 (ja) 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子
CN118001254B (zh) 靶向抗原呈递细胞的脂质组合物及其应用
CN104983716A (zh) 肿瘤细胞膜/核膜双靶向肿瘤纳米药物缓释系统及其制备与应用
WO2025200517A1 (zh) 一种用于核酸递送的脂质材料及其用途
US20240016940A1 (en) Long-acting and long-circulating delivery vehicles
CN109550057B (zh) 主动靶向型基因递送纳米粒及其制备方法和应用
US11260068B2 (en) Long-circulating liposome modified with c(RGD-ACP-K)
US12396949B2 (en) Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substituted with a silicon atom
JP2003529550A (ja) リポソーム封入されたdna経口ワクチン
WO2026052844A1 (en) 3-component lipid nanoparticle compositions, uses, and manufacturing methods thereof
BR102025005957A2 (pt) Composição lipídica, uso de uma composição lipídica, composição, método de preparação de uma composição para a administração de um agente terapêutico e/ou profilático às células que apresentam antígenos em órgãos alvo e uso
HK40060954A (en) Lipid nanoparticle
WO2023024511A1 (zh) 新型阳离子脂质化合物(一)
CN119818705A (zh) 一种mRNA组合物及其应用
AU2024342596A1 (en) Material for local drug delivery, and use thereof
CN121045013A (zh) 一种可电离阳离子脂质化合物及其制备方法和应用